Venetian-1 Acquisition Corp. Business Finance Contracts & Agreements
12 Contracts & Agreements
- Assignment Agreements (2 contracts)
- Note Agreements (6)
- Registration Rights Agreements (1)
- Stock Agreements (1)
- Subscription Agreements (1)
- Warrant Agreements (1)
- Assignment and Consent Agreement, dated as of December 7, 2023, by and among Lomond Therapeutics, Inc., Eilean Therapeutics, LLC. and Dinas Therapeutics, Inc (Filed With SEC on November 7, 2024)
- Assignment and Consent Agreement, dated as of December 7, 2023, by and among Lomond Therapeutics, Inc., Eilean Therapeutics, LLC. and Eil Therapeutics, Inc (Filed With SEC on November 7, 2024)
- Promissory Note, dated as of January 5, 2023, by and between Lomond Therapeutics, Inc. and Eil Therapeutics, Inc (Filed With SEC on November 7, 2024)
- Promissory Note, dated as of December 1, 2023, by and between Lomond Therapeutics, Inc. and Eil Therapeutics, Inc (Filed With SEC on November 7, 2024)
- Promissory Note, dated as of June 21, 2022, by and between Lomond Therapeutics, Inc. and Dinas Therapeutics, Inc (Filed With SEC on November 7, 2024)
- Promissory Note, dated as of May 2, 2022, by and between Lomond Therapeutics, Inc. and Dinas Therapeutics, Inc (Filed With SEC on November 7, 2024)
- Promissory Note, dated as of October 17, 2024, by and between Lomond Therapeutics, Inc. and Bala Therapeutics, Inc (Filed With SEC on November 7, 2024)
- Promissory Note, dated as of October 17, 2024, by and between Lomond Therapeutics, Inc. and Eil Therapeutics, Inc (Filed With SEC on November 7, 2024)
- Lomond Therapeutics, Inc. 2024 Stock Plan and form of award agreements thereunder (Filed With SEC on November 7, 2024)
- Registration Rights Agreement, dated November 1, 2024, by and between the Company and the parties thereto (Filed With SEC on November 7, 2024)
- Subscription Agreement, dated November 1, 2024, by and between the Company and the parties thereto (Filed With SEC on November 7, 2024)
- Form of Placement Agent Warrant (Filed With SEC on November 7, 2024)
